BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 22932803)

  • 21. CD40-independent natural killer-cell help promotes dendritic cell vaccine-induced T-cell immunity against endogenous B-cell lymphoma.
    Hömberg N; Adam C; Riedel T; Brenner C; Flatley A; Röcken M; Mocikat R
    Int J Cancer; 2014 Dec; 135(12):2825-33. PubMed ID: 24771135
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Natural killer T cell ligand alpha-galactosylceramide protects against gut ischemia reperfusion-induced organ injury in mice.
    Zhang J; Bi J; Ren Y; Du Z; Li T; Li Q; Ke M; Dong J; Lv Y; Wu R
    Cytokine; 2018 Nov; 111():237-245. PubMed ID: 30195979
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activating immunity in the liver. II. IFN-beta attenuates NK cell-dependent liver injury triggered by liver NKT cell activation.
    Trobonjaca Z; Kröger A; Stober D; Leithäuser F; Möller P; Hauser H; Schirmbeck R; Reimann J
    J Immunol; 2002 Apr; 168(8):3763-70. PubMed ID: 11937527
    [TBL] [Abstract][Full Text] [Related]  

  • 24. alpha-Galactosylceramide enhances the protective and therapeutic effects of tumor cell based vaccines for ovarian tumors.
    Choi YS; Hoory T; Monie A; Wu A; Connolly D; Hung CF
    Vaccine; 2008 Oct; 26(46):5855-63. PubMed ID: 18771701
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced gamma interferon production through activation of Valpha14(+) natural killer T cells by alpha-galactosylceramide in interleukin-18-deficient mice with systemic cryptococcosis.
    Kawakami K; Kinjo Y; Yara S; Uezu K; Koguchi Y; Tohyama M; Azuma M; Takeda K; Akira S; Saito A
    Infect Immun; 2001 Nov; 69(11):6643-50. PubMed ID: 11598033
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel function of Valpha14+CD4+NKT cells: stimulation of IL-12 production by antigen-presenting cells in the innate immune system.
    Tomura M; Yu WG; Ahn HJ; Yamashita M; Yang YF; Ono S; Hamaoka T; Kawano T; Taniguchi M; Koezuka Y; Fujiwara H
    J Immunol; 1999 Jul; 163(1):93-101. PubMed ID: 10384104
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Control of B-cell lymphoma by therapeutic vaccination and acquisition of immune resistance is independent of direct tumour IFN-gamma signalling.
    Rearden R; Sah A; Doff B; Kobayashi T; McKee SJ; Leggatt GR; Mattarollo SR
    Immunol Cell Biol; 2016 Jul; 94(6):554-62. PubMed ID: 26786233
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A simple, clinically relevant therapeutic vaccine shows long-term protection in an aggressive, delayed-treatment B lymphoma model.
    Pradhan P; Leleux J; Liu J; Roy K
    JCI Insight; 2017 Nov; 2(22):. PubMed ID: 29202455
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy.
    Thapa P; Zhang G; Xia C; Gelbard A; Overwijk WW; Liu C; Hwu P; Chang DZ; Courtney A; Sastry JK; Wang PG; Li C; Zhou D
    Vaccine; 2009 May; 27(25-26):3484-8. PubMed ID: 19200815
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IL-18 enhances IL-4 production by ligand-activated NKT lymphocytes: a pro-Th2 effect of IL-18 exerted through NKT cells.
    Leite-De-Moraes MC; Hameg A; Pacilio M; Koezuka Y; Taniguchi M; Van Kaer L; Schneider E; Dy M; Herbelin A
    J Immunol; 2001 Jan; 166(2):945-51. PubMed ID: 11145671
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity.
    Fujii S; Shimizu K; Hemmi H; Steinman RM
    Immunol Rev; 2007 Dec; 220():183-98. PubMed ID: 17979847
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A critical role for IFN regulatory factor 1 in NKT cell-mediated liver injury induced by alpha-galactosylceramide.
    Cao Z; Dhupar R; Cai C; Li P; Billiar TR; Geller DA
    J Immunol; 2010 Aug; 185(4):2536-43. PubMed ID: 20624945
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted delivery of α-galactosylceramide to CD8α+ dendritic cells optimizes type I NKT cell-based antitumor responses.
    Macho-Fernandez E; Cruz LJ; Ghinnagow R; Fontaine J; Bialecki E; Frisch B; Trottein F; Faveeuw C
    J Immunol; 2014 Jul; 193(2):961-9. PubMed ID: 24913977
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Activation of natural killer T cells by NK-4, a criptocyanine dye].
    Kunikata T; Kohno K; Ushio S; Fukuda S
    Yakugaku Zasshi; 2011; 131(11):1667-74. PubMed ID: 22041707
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Critical contribution of IFN-gamma and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of alpha-galactosylceramide.
    Hayakawa Y; Takeda K; Yagita H; Kakuta S; Iwakura Y; Van Kaer L; Saiki I; Okumura K
    Eur J Immunol; 2001 Jun; 31(6):1720-7. PubMed ID: 11385616
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanism of NKT cell activation by intranasal coadministration of alpha-galactosylceramide, which can induce cross-protection against influenza viruses.
    Kamijuku H; Nagata Y; Jiang X; Ichinohe T; Tashiro T; Mori K; Taniguchi M; Hase K; Ohno H; Shimaoka T; Yonehara S; Odagiri T; Tashiro M; Sata T; Hasegawa H; Seino KI
    Mucosal Immunol; 2008 May; 1(3):208-18. PubMed ID: 19079180
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimization of natural killer T cell-mediated immunotherapy in cancer using cell-based and nanovector vaccines.
    Faveeuw C; Trottein F
    Cancer Res; 2014 Mar; 74(6):1632-8. PubMed ID: 24599135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In Vivo Inverse Correlation in the Activation of Natural Killer T Cells Through Dual-Signal Stimulation via a Combination of α-Galactosylceramide-Loaded Liposomes and Interleukin-12.
    Abdelmegeed H; Nakamura T; Harashima H
    J Pharm Sci; 2016 Jan; 105(1):250-6. PubMed ID: 26852856
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo antitumor activity of NKT cells activated by the combination of IL-12 and IL-18.
    Baxevanis CN; Gritzapis AD; Papamichail M
    J Immunol; 2003 Sep; 171(6):2953-9. PubMed ID: 12960319
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Defining a novel subset of CD1d-dependent type II natural killer T cells using natural killer cell-associated markers.
    Singh AK; Rhost S; Löfbom L; Cardell SL
    Scand J Immunol; 2019 Sep; 90(3):e12794. PubMed ID: 31141185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.